Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 4
2010 5
2011 5
2012 4
2013 1
2014 4
2016 1
2017 1
2018 1
2020 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.
Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A. Gangat N, et al. Among authors: caramazza d. J Clin Oncol. 2011 Feb 1;29(4):392-7. doi: 10.1200/JCO.2010.32.2446. Epub 2010 Dec 13. J Clin Oncol. 2011. PMID: 21149668
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.
Mora B, Guglielmelli P, Kuykendall A, Rumi E, Maffioli M, Palandri F, De Stefano V, Caramella M, Salmoiraghi S, Kiladjian JJ, Gotlib J, Iurlo A, Cervantes F, Ruggeri M, Silver RT, Albano F, Benevolo G, Ross DM, Della Porta MG, Devos T, Rotunno G, Komrokji RS, Casetti IC, Merli M, Brociner M, Caramazza D, Auteri G, Barbui T, Cattaneo D, Bertù L, Arcaini L, Vannucchi AM, Passamonti F. Mora B, et al. Among authors: caramazza d. Leukemia. 2022 Oct;36(10):2453-2460. doi: 10.1038/s41375-022-01673-3. Epub 2022 Aug 30. Leukemia. 2022. PMID: 36042316
Clinical predictors of outcome in MPN.
Passamonti F, Maffioli M, Merli M, Ferrario A, Caramazza D. Passamonti F, et al. Among authors: caramazza d. Hematol Oncol Clin North Am. 2012 Oct;26(5):1101-16. doi: 10.1016/j.hoc.2012.07.009. Epub 2012 Aug 28. Hematol Oncol Clin North Am. 2012. PMID: 23009940 Review.
Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry.
Agosti P, De Leo P, Capecchi M, Ferrari B, Mancini I, Gattillo S, Trisolini SM, Rinaldi E, Podda GM, Prezioso L, Salutari P, Facchini L, Caramazza D, Tolomelli G, Artoni A, Peyvandi F. Agosti P, et al. Among authors: caramazza d. Res Pract Thromb Haemost. 2023 Aug 26;7(6):102185. doi: 10.1016/j.rpth.2023.102185. eCollection 2023 Aug. Res Pract Thromb Haemost. 2023. PMID: 37720483 Free PMC article.
It is time to change thrombosis risk assessment for PV and ET?
Passamonti F, Caramazza D, Mora B, Casalone R, Maffioli M. Passamonti F, et al. Among authors: caramazza d. Best Pract Res Clin Haematol. 2014 Jun;27(2):121-7. doi: 10.1016/j.beha.2014.07.005. Epub 2014 Jul 18. Best Pract Res Clin Haematol. 2014. PMID: 25189723 Review.
JAK inhibitor in CALR-mutant myelofibrosis.
Passamonti F, Caramazza D, Maffioli M. Passamonti F, et al. Among authors: caramazza d. N Engl J Med. 2014 Mar 20;370(12):1168-9. doi: 10.1056/NEJMc1400499. N Engl J Med. 2014. PMID: 24645956 No abstract available.
Novel agents in indolent lymphomas.
Merli M, Ferrario A, Basilico C, Maffioli M, Caramazza D, Appio L, Arcaini L, Passamonti F. Merli M, et al. Among authors: caramazza d. Ther Adv Hematol. 2013 Apr;4(2):133-48. doi: 10.1177/2040620712466865. Ther Adv Hematol. 2013. PMID: 23610620 Free PMC article.
25 results